{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T06:09:14Z","timestamp":1778652554589,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100020956","name":"Merck Healthcare KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10557-025-07753-7","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T04:26:30Z","timestamp":1753676790000},"page":"911-921","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of Bisoprolol Versus Other Beta-Blockers on Glycemic Control and Metabolic Parameters in Type 2 Diabetes: A Retrospective Cohort Study"],"prefix":"10.1007","volume":"40","author":[{"given":"Sivan","family":"Gazit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2702-6115","authenticated-orcid":false,"given":"Yogev","family":"Yonatan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moshe Baruch","family":"Hoshen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Mahfoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tal Tova","family":"Patalon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"issue":"5","key":"7753_CR1","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s10557-021-07205-y","volume":"36","author":"W AlHabeeb","year":"2022","unstructured":"AlHabeeb W, Mrabeti S, Abdelsalam AAI. Therapeutic properties of highly selective \u03b2-blockers with or without additional vasodilator properties: focus on Bisoprolol and Nebivolol in patients with cardiovascular disease. Cardiovasc Drugs Ther. 2022;36(5):959\u201371. https:\/\/doi.org\/10.1007\/s10557-021-07205-y","journal-title":"Cardiovasc Drugs Ther"},{"issue":"12","key":"7753_CR2","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874\u20132071. https:\/\/doi.org\/10.1097\/HJH.0000000000003480","journal-title":"J Hypertens"},{"issue":"sup1","key":"7753_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/03007995.2024.2318058","volume":"40","author":"S Taddei","year":"2024","unstructured":"Taddei S, Tsabedze N, Tan RS. \u0392-blockers are not all the same: pharmacologic similarities and differences, potential combinations and clinical implications. Curr Med Res Opin. 2024;40(sup1):15\u201323. https:\/\/doi.org\/10.1080\/03007995.2024.2318058","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"7753_CR4","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891\u2013975. https:\/\/doi.org\/10.1002\/ejhf.592.","journal-title":"Eur J Heart Fail"},{"issue":"39","key":"7753_CR5","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1093\/eurheartj\/ehz687","volume":"40","author":"PJ Grant","year":"2019","unstructured":"Grant PJ, Cosentino F. The 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019;40(39):3215\u20137. https:\/\/doi.org\/10.1093\/eurheartj\/ehz687","journal-title":"Eur Heart J"},{"issue":"6","key":"7753_CR6","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. Hypertension. 2018;71(6):1269\u2013324. https:\/\/doi.org\/10.1161\/HYP.0000000000000066","journal-title":"Hypertension"},{"key":"7753_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejim.2021.03.035","volume":"88","author":"S Paolillo","year":"2021","unstructured":"Paolillo S, Dell\u2019Aversana S, Esposito I, Poccia A, Perrone FP. The use of \u03b2-blockers in patients with heart failure and comorbidities: doubts, certainties and unsolved issues. Eur J Intern Med. 2021;88:9\u201314. https:\/\/doi.org\/10.1016\/j.ejim.2021.03.035","journal-title":"Eur J Intern Med"},{"issue":"12","key":"7753_CR8","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1517\/14740338.2015.1102225","volume":"14","author":"RG Kiel","year":"2015","unstructured":"Kiel RG, Deedwania P. The safety and tolerability of beta blockers in heart failure with reduced ejection fraction: is the current underutilization of this evidence-based therapy justified? Expert Opin Drug Saf. 2015;14(12):1855\u201363. https:\/\/doi.org\/10.1517\/14740338.2015.1102225","journal-title":"Expert Opin Drug Saf"},{"key":"7753_CR9","unstructured":"Characterization and classification of geographical units by the socio\u2010economic level of the population. Israel Central Bureau of Statistics; 2019. https:\/\/www.cbs.gov.il\/he\/publications\/DocLib\/2021\/socio_eco17_1832\/e_print.pdf"},{"issue":"3","key":"7753_CR10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ijcard.2010.08.002","volume":"152","author":"V Shalev","year":"2011","unstructured":"Shalev V, Chodick G, Goren I, Silber H, Kokia E, Heymann AD. The use of an automated patient registry to manage and monitor cardiovascular conditions and related outcomes in a large health organization. Int J Cardiol. 2011;152(3):345\u20139. https:\/\/doi.org\/10.1016\/j.ijcard.2010.08.002","journal-title":"Int J Cardiol"},{"issue":"12","key":"7753_CR11","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1023\/B:EJEP.0000006635.36802.c8","volume":"18","author":"G Chodick","year":"2002","unstructured":"Chodick G, Heymann AD, Shalev V, Kookia E. The epidemiology of diabetes in a large Israeli HMO. Eur J Epidemiol. 2002;18(12):1143\u20136. https:\/\/doi.org\/10.1023\/B:EJEP.0000006635.36802.c8","journal-title":"Eur J Epidemiol"},{"key":"7753_CR12","unstructured":"The Israel Cancer Association. The Israel Cancer Association. Accessed December 30, 2024. http:\/\/en.cancer.org.il"},{"issue":"3","key":"7753_CR13","doi-asserted-by":"publisher","first-page":"e00750","DOI":"10.1002\/prp2.750","volume":"9","author":"M Dankers","year":"2021","unstructured":"Dankers M, Nelissen-Vrancken MHJMG, Hart BH, Lambooij AC, van Dijk L, Mantel-Teeuwisse AK. Alignment between outcomes and minimal clinically important differences in the Dutch type 2 diabetes mellitus guideline and healthcare professionals\u2019 preferences. Pharmacol Res Perspect. 2021;9(3):e00750. https:\/\/doi.org\/10.1002\/prp2.750.","journal-title":"Pharmacol Res Perspect"},{"issue":"11","key":"7753_CR14","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1097\/CM9.0000000000001407","volume":"134","author":"YL Zhou","year":"2021","unstructured":"Zhou YL, Zhang YG, Zhang R, et al. Population diversity of cardiovascular outcome trials and real-world patients with diabetes in a Chinese tertiary hospital. Chin Med J (Engl). 2021;134(11):1317\u201323. https:\/\/doi.org\/10.1097\/CM9.0000000000001407.","journal-title":"Chin Med J (Engl)"},{"issue":"2","key":"7753_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15226\/2374-6890\/4\/2\/00175","volume":"4","author":"Y Sirenko","year":"2017","unstructured":"Sirenko Y. Effect of beta - blockers on insulin resistance in patients with hypertension and metabolic syndrome after 6 months of treatment. J Endocrinol Diabetes. 2017;4(2):1\u201311. https:\/\/doi.org\/10.15226\/2374-6890\/4\/2\/00175","journal-title":"J Endocrinol Diabetes"},{"issue":"3","key":"7753_CR16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1185\/03007990903533681","volume":"26","author":"VA Fonseca","year":"2010","unstructured":"Fonseca VA. Effects of \u03b2-blockers on glucose and lipid metabolism. Curr Med Res Opin. 2010;26(3):615\u201329. https:\/\/doi.org\/10.1185\/03007990903533681","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"7753_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1475-2840-11-14","volume":"11","author":"B Wai","year":"2012","unstructured":"Wai B, Kearney LG, Hare DL, Ord M, Burrell LM, Srivastava PM. Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control. Cardiovasc Diabetol. 2012;11(1):14. https:\/\/doi.org\/10.1186\/1475-2840-11-14","journal-title":"Cardiovasc Diabetol"},{"issue":"Suppl 5","key":"7753_CR18","doi-asserted-by":"publisher","first-page":"S175","DOI":"10.1097\/00005344-199000165-00031","volume":"16","author":"HG Giesecke","year":"1990","unstructured":"Giesecke HG, Buchner-M\u00f6ll D. Three years of experience with bisoprolol in the treatment of mild to moderate hypertension. J Cardiovasc Pharmacol. 1990;16(Suppl 5):S175-178.","journal-title":"J Cardiovasc Pharmacol"},{"key":"7753_CR19","doi-asserted-by":"publisher","unstructured":"Janka HU, Ziegler AG, Disselhoff G, Mehnert H. Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin-dependent diabetics. J Cardiovasc Pharmacol. 1985;8:S96-S99. https:\/\/doi.org\/10.1097\/00005344-198511001-00018","DOI":"10.1097\/00005344-198511001-00018"},{"issue":"1","key":"7753_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2174\/1573402114666180918102735","volume":"15","author":"GT Do Vale","year":"2019","unstructured":"Do Vale GT, Ceron CS, Gonzaga NA, Simplicio JA, Padovan JC. Three generations of \u03b2-blockers: history, class differences and clinical applicability. Curr Hypertens Rev. 2019;15(1):22\u201331. https:\/\/doi.org\/10.2174\/1573402114666180918102735","journal-title":"Curr Hypertens Rev"},{"issue":"1","key":"7753_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.12775\/JEHS.2023.23.01.005","volume":"23","author":"K Fularska","year":"2023","unstructured":"Fularska K, Oleszko M, W\u0105siewicz E, Ku\u017aniar A, Szawica D. Beta-blockers used in cardiac failure and blood glucose level impairment - a literature review. J Educ Health Sport. 2023;23(1):40\u201351. https:\/\/doi.org\/10.12775\/JEHS.2023.23.01.005","journal-title":"J Educ Health Sport"},{"key":"7753_CR22","doi-asserted-by":"publisher","unstructured":"Verdecchia P, Grossman E, Whelton P. 2023 ESH guidelines. What are the main recommendations? Eur J Intern Med. 2023;116:1\u20137. https:\/\/doi.org\/10.1016\/j.ejim.2023.07.034","DOI":"10.1016\/j.ejim.2023.07.034"},{"issue":"2","key":"7753_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2165\/00002018-199615020-00005","volume":"15","author":"JC Chan","year":"1996","unstructured":"Chan JC, Cockram CS, Critchley JA. Drug-induced disorders of glucose metabolism. Mechanisms and management. Drug Saf. 1996;15(2):135\u201357. https:\/\/doi.org\/10.2165\/00002018-199615020-00005","journal-title":"Drug Saf"},{"issue":"7","key":"7753_CR24","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/qjmed\/hcl059","volume":"99","author":"PA Sarafidis","year":"2006","unstructured":"Sarafidis PA. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM. 2006;99(7):431\u20136. https:\/\/doi.org\/10.1093\/qjmed\/hcl059","journal-title":"QJM"},{"issue":"1","key":"7753_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/FJC.0000000000000543","volume":"71","author":"Y Park","year":"2018","unstructured":"Park Y, Choi BG, Rha SW, et al. Selective \u00df1-blockers are not associated with new-onset diabetes mellitus in hypertensive patients. J Cardiovasc Pharmacol. 2018;71(1):38\u201345. https:\/\/doi.org\/10.1097\/FJC.0000000000000543.","journal-title":"J Cardiovasc Pharmacol"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07753-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-025-07753-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07753-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:21:15Z","timestamp":1778649675000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-025-07753-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7753"],"URL":"https:\/\/doi.org\/10.1007\/s10557-025-07753-7","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"9 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest in this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}},{"value":"This study was approved by the MHS Institutional Review Board (MHS-0001\u201324). Owing to the retrospective design of the study, informed consent was waived by the IRB and all identifying details of the participants were removed before computational analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}